Muscle Relaxation for Pediatric Adenotonsillectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions
Tonsillectomy
Interventions
DRUG

Rocuronium

After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.

DRUG

Sugammadex

When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.

OTHER

Anesthesia without neuromuscular blockade

Anesthesia without rocuronium or sugammadex

Trial Locations (1)

75235

Children's Health Dallas, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT06225466 - Muscle Relaxation for Pediatric Adenotonsillectomy | Biotech Hunter | Biotech Hunter